Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Spondyloarthritis

Upadacitinib Application for Active Psoriatic Arthritis Submitted for Review

Brian Park, PharmD

June 11, 2020

AbbVie has submitted an application to the FDA for review of upadacitinib in the treatment of active psoriatic arthritis (PsA) in adults.

Scleroderma

FDA Grants Orphan Drug Status to Antifibrotic Therapy for Systemic Sclerosis

Brian Park, PharmD

June 2, 2020

The FDA has granted Orphan Drug designation to TLY012 for the treatment of systemic sclerosis.

General Rheumatology

Large Study Finds No Benefit of Hydroxychloroquine or Chloroquine for COVID-19

Brian Park, PharmD

June 1, 2020

Use of hydroxychloroquine or chloroquine may increase the risk of ventricular arrhythmia and death in patients hospitalized.

Systemic Lupus Erythematosus

Voclosporin NDA for Lupus Nephritis Submitted to the FDA

Brian Park, PharmD

May 29, 2020

The NDA for voclosporin has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.

Pain Management

Unapproved Cannabidiol, Curcumin Injectables for Multiple Disorders Recalled

Brian Park, PharmD

May 28, 2020

Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.

Pediatric Rheumatology

Golimumab sBLAs for JIA, Juvenile Psoriatic Arthritis Submitted for FDA Review

Brian Park, PharmD

April 28, 2020

A sBLA has been submitted ot the FDA for golimumab for the treatment of polyarticular juvenile idiopathic arthritis and juvenile PsA in combination with methotrexate.

General Rheumatology

FDA Greenlights Novartis Trial Investigating Hydroxychloroquine for COVID-19

Brian Park, PharmD

April 27, 2020

Novartis will make its hydroxychloroquine intellectual property available to support broad access for the treatment if it is approved for COVID-19.

Systemic Lupus Erythematosus

Telitacicept Fast-Tracked for the Treatment of Systemic Lupus Erythematosus

Brian Park, PharmD

April 24, 2020

The FDA has granted Fast Track designation to telitacicept for the treatment of systemic lupus erythematosus.

Pain Management

FDA Approves NDA for Diclofenac Sodium Topical Gel 1% for Arthritis Pain

Brian Park, PharmD

April 13, 2020

Perrigo announced that the FDA has approved the abbreviated New Drug Application for its over-the-counter diclofenac sodium topical gel 1% for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults ≥18 years old.

General Rheumatology

FDA: Studies Underway to Evaluate Chloroquine for COVID-19

Brian Park, PharmD

March 25, 2020

The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).

Next post in General Rheumatology